1Brambilla E,Travis WD,Colby TV,et al.The new World Health Organization classification of lung tumours[J].Eur Respir J,2001,18:1059-1068.
2NCCN clinical practice guidelines in oncology:non-small cell lung cancer.version 2,2011.
3Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346:92-97.
4Scagliotti GV,Parikh P,Pawel JV,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer[J]. J Clin Oncol,2008,26:3543-3551.
5Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350:2129-2139.
6Kosaka T,Yatabe Y,Endoh H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer:biological and clinical implications[J].Cancer Res,2004,64:8919-8923.
7Forbes SA,Bharma G,Bamford S,et al.The catalogue of somatic mutations in cancer (COSMIS) [J].Curr Protoc Hum Genet,2008,chapter 10:unit 10-11.
8Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361:947-957.
9Zhou C,Wu YL,et al.Efficacy results from the randomized phase Ⅲ optimal study comparing first-line erlotinib versus carboplatin plus gemcitabine,in Chinese advanced non-small-cell lung cancer patients with EGFR activating mutations[J].Ann Oncol,2010,21 (Suppl 8).
10Pirker R,Periera JR,Szczesna A,et al. Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX):an open label randomized phase Ⅲ trial[J].Lancet,2009,373:1525-1531.
